Enrico Farnetti

Enrico Farnetti

Auto-generated profile, based on publicly available information

Enrico Farnetti

Molecular Biology Laboratory, Arcispedale Santa Maria Nuova-IRCCS, Reggio Emilia, Italy

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2016 in Annals of the Rheumatic Diseases
Verified
Journal Article
Closed access
PDF file
Stefania CrociStefania Croci
Stefania Croci
AZAlessandro Zerbini
Alessandro Zerbini
LBLuigi Boiardi
Luigi Boiardi
Francesco MuratoreFrancesco Muratore
Francesco Muratore
ABAlessandra Bisagni
Alessandra Bisagni
SCSalvarani Carlo
Salvarani Carlo
Objectives There is increasing evidence that microRNAs (miRNAs) are deregulated in autoimmune and cardiovascular diseases. The present study aimed to identify if miRNAs are deregulated in giant cell arteritis (GCA), a vasculitis affecting large-sized and medium-sized arteries, and to determine if miRNA levels might allow to discriminate between patients with GCA and those without. Methods 58 patients who had temporal artery biopsy (TAB) for suspected GCA were included in the study and divided into three groups: patients with TAB-positive GCA showing a transmural inflammation (n=27), patients with TAB-negative GCA (n=8) and TAB-negative non-GCA patients with a final diagnosis different from GCA (n=23). To identify candidate miRNAs deregulated in GCA, we profiled the expression of 1209 miRNAs in inflamed TABs and normal TABs. Selected miRNAs were then validated by real-time PCRs and in situ hybridisation (ISH). Results MiR-146b-5p, -146a, -155, -150, -21 and -299-5p were significantly more expressed in inflamed TABs from patients with GCA. miRNAs were mainly deregulated at the tissue level because peripheral blood mononuclear cells and polymorphonuclear cells from the three groups of patients and age-matched healthy controls had similar levels of miRNAs. ISH showed that miR-21 was mainly expressed by cells in the medial and intimal layers of inflamed TABs. Patients with TAB-negative GCA had a miRNA profile similar to TAB-negative non-GCA patients. Conclusions MiR-146b-5p, -146a, -21, -150, -155, -299-5p are overexpressed in the presence of inflammation in TABs from patients with GCA.

28 November 2006 in Arthritis & Rheumatism
Verified
Journal Article
Open access
PDF file
LBLuigi Boiardi
Luigi Boiardi
BCBruno Casali
Bruno Casali
EFEnrico Farnetti
Enrico Farnetti
NPNicolò Pipitone
Nicolò Pipitone
DNDavide Nicoli
Davide Nicoli
SCSalvarani Carlo
Salvarani Carlo
Objective: To investigate potential associations between interleukin‐10 (IL‐10) promoter polymorphisms and susceptibility to, and clinical features of, giant cell arteritis (GCA).Methods: A total of 140 patients with biopsy‐proven GCA who were residents of Reggio Emilia, Italy, and 200 population‐based controls from the same geographic area were genotyped for promoter polymorphisms of the IL‐10 gene, by molecular methods. The patients were subgrouped according to the presence or absence of polymyalgia rheumatica (PMR) and ischemic complications (any or all of the following: vision loss, jaw claudication, cerebrovascular accidents, or aortic arch syndrome).Results: The distribution of the C/A 592 genotype differed significantly between the GCA patients and the controls (Pcorr = 0.003). Carriers of the A592 allele (A/A or C/A) were significantly more frequent among the GCA patients than among the controls (Pcorr = 0.004, odds ratio [OR] 2.0 [95% confidence interval (95% CI) 1.3–3.1]). Homozygosity for the A592 allele was significantly more frequent among the GCA patients than among the controls (Pcorr = 0.002, OR 3.4 [95% CI 1.6–7.2]). The distribution of the A/G 1082 genotype was similar in GCA patients and controls. In the haplotype analysis, the frequency of the ATA haplotype was significantly higher in GCA patients than in the controls (P = 0.0001), whereas the frequencies of the ACC and GTA haplotypes were significantly lower (P = 0.0001 for both comparisons). No significant associations were found for comparisons of GCA patients with and those without PMR or GCA patients with and those without ischemic complications.Conclusion: Our findings show that the −592 C/A promoter polymorphism of the IL‐10 gene is associated with susceptibility to GCA.

8 November 2002 in Arthritis & Rheumatism
Verified
Journal Article
Open access
PDF file
SCSalvarani Carlo
Salvarani Carlo
EFEnrico Farnetti
Enrico Farnetti
BCBruno Casali
Bruno Casali
DNDavide Nicoli
Davide Nicoli
LWLiu Wenlan
Liu Wenlan
FCFabrizio Cantini
Fabrizio Cantini
Click on the article title to read more.

7 September 2012 in Rheumatology International
Verified
Journal Article
Closed access
PDF file
MCMaria Grazia Catanoso
Maria Grazia Catanoso
LBLuigi Boiardi
Luigi Boiardi
PMPierluigi Macchioni
Pierluigi Macchioni
PGPaolo Garagnani
Paolo Garagnani
MSMarco Sazzini
Marco Sazzini
SCSalvarani Carlo
Salvarani Carlo

12 March 2019 in British Journal of Cancer
Verified
Journal Article
Open access
PDF file
FIFrancesco Iachetta
Francesco Iachetta
CBCandida Bonelli
Candida Bonelli
ARAlessandra Romagnani
Alessandra Romagnani
RZRaffaella Zamponi
Raffaella Zamponi
LTLorenzo Tofani
Lorenzo Tofani
CPCarmine Pinto
Carmine Pinto
Background Deleterious polymorphisms in the gene encoding DPD (DPYD) may result in severe reduction of DPD enzymatic activity that causes life-threatening toxicities when the standard dose of fluorouracil is used. The best panel of single-nucleotide polymorphism (SNPs) of DPYD is not well defined. Methods In 2011, we began screening DPYD*2A in patients candidate for fluoropyrimidine-based chemotherapy. We planned a case-control study with all cases of DPYD*2A wild type who developed toxicity ≥G3 and with a cohort of patients who did not present severe toxicities. Then, we tested the additional SNPs: c.2846A>T, c.1679T>G, c.2194G>A. Results From 2011 to 2016, we screened 1827 patients for DPD deficiency; of those, 31 subjects (1.7%) showed DPYD*2A SNP. We selected 146 subjects who developed severe toxicities (Cases) and 220 patients who experienced no or mild toxicities (Controls); 53 patients carried one of the additional SNPs: 35 subjects (66%) fell into the Cases and 18 (34%) into the Controls (p < 0.0001). c.2194G>A was the most frequent SNP (12.5%) and showed a correlation with neutropenia. We confirmed that c.2846A>T and c.1679T>G were related to various toxicities. Conclusions The additional DPYD polymorphisms could enhance the prevention of fluoropyrimidine toxicity. c.2194G>A is the most frequent polymorphism and it was found to be associated with neutropenia.

1 May 2008 in Journal Of Hypertension
Verified
Journal Article
Closed access
ERErmanno Rossi
Ermanno Rossi
EFEnrico Farnetti
Enrico Farnetti
ADAnne Debonneville
Anne Debonneville
DNDavide Nicoli
Davide Nicoli
CGChiara Grasselli
Chiara Grasselli
OSOlivier Staub
Olivier Staub
The aim of the study was to search for mutations of SCNN1B and SCNN1G in an Italian family with apparently dominant autosomal transmission of a clinical phenotype consistent with Liddle's syndrome. Genetic analysis was performed in the proband, his relatives, and 100 control subjects. To determine the functional role of the mutation identified in the proband, we expressed the mutant or wild-type epithelial sodium channel in Xenopus laevis oocytes. A novel point mutation, causing an expected substitution of a leucine residue for the second proline residue of the conserved PY motif (PPP x Y) of the beta subunit was identified in the proband. The functional expression of the mutant epithelial sodium channel in X. laevis oocytes showed a three-fold increase in the amiloride-sensitive current as compared with that of the wild-type channel. This newly identified mutation adds to other missense mutations of the PY motif of the beta subunit of the epithelial sodium channel, thus confirming its crucial role in the regulation of the epithelial sodium channel. To our knowledge, this is the first report of Liddle's syndrome in the Italian population, confirmed by genetic and functional analysis, with the identification of a gain-of-function mutation not previously reported.